management technical assistance may be obtained from Locke Thompson, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC), 255 East Paces Ferry Road, NE., Room 314, Mail Stop E–18, Atlanta, GA 30305, telephone (404) 842–6595.

Programmatic technical assistance may be obtained from Michael E. Dalmat, Dr.P.H., Division of Reproductive Health, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention (CDC), 4770 Buford Highway, NE., Mail Stop K–20, Atlanta, GA 30341–3724, telephone (404) 488–5136.

Please refer to Announcement Number 547 when requesting information and submitting an application.


Arthur C. Jackson,
Associate Director for Management and Operations, Centers for Disease Control And Prevention (CDC).

[FR Doc. 95–17415 Filed 7–13–95; 8:45 am] SUPPLEMENTARY INFORMATION :

FDA is announcing the availability of a guideline entitled "Guideline for Quality Assurance in Blood Establishments" (HFA–305), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–594–3074.

The guideline includes discussions of the following: (1) The general concepts of a quality control/assurance program; (2) the function and reporting responsibilities of the QA unit; (3) the responsibilities of the QA unit in such areas as standard operating procedures, training and education, competency evaluation, proficiency testing, validation, equipment, error/accident reports, records management, lot release procedures and QA audits; and (4) the

Food and Drug Administration

[DOCKET NO. 1109–0050]

Guideline for Quality Assurance in Blood Establishments; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing the availability of a guideline entitled “Guideline for Quality Assurance in Blood Establishments.” This guideline is intended to assist manufacturers of blood and blood components, including blood banks, blood centers, transfusion services, and plasmapheresis centers, in developing quality assurance (QA) programs that are consistent with recognized principles of QA and current good manufacturing practice (CGMP).

This guideline revises the draft “Guideline for Quality Assurance in Blood Establishments,” dated June 17, 1993, and provides general information on procedures and practices that may be useful to blood establishments in developing and administering a QA program.

DATES: Written comments may be submitted at any time.


Persons with access to the INTERNET may request the guideline be sent by return email by sending a message to “GDE–QA@CBER.FDA.GOV.” The guideline may also be obtained through INTERNET via File Transfer Protocol (FTP). Requestors should connect to the Center for Drug Evaluation and Research (CDER) FTP using the FTP. The Center for Biologics Evaluation and Research (CBER) documents are maintained in a subdirectory called CBER on the server, “CDV2.CBER.FDA.GOV.” The “READ.ME” file in that subdirectory describes the available documents, which may be available as an ASCII text file (*.TXT), or a WordPerfect 5.1 document (*.W51), or both. A sample dialogue for obtaining the READ.ME file with a test based FTP program would be:

FTP CDV2.CBER.FDA.GOV LOGIN ANONYMOUS <ANY PASSWORD>
BINARY
CD CBER
GET READ.ME
EXIT

The guideline may also be obtained by calling the CBER FAX Information System (FAX–ON–DEMAND) at 301–594–1939 from a FAX machine with a touch tone phone attached or built-in.

Submit written comments on this guideline to the Dockets Management Branch (HFA–305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857. Requests and comments should be identified with the docket number found in brackets in the heading of this document. Two copies of any comments are to be submitted, except that individual may submit one copy. Requests and comments should be identified with the docket number found in brackets in the heading of this document. The “Guideline for Quality Assurance in Blood Establishments” and received comments are available for public examination in the Dockets Management Branch (address above) between 9 a.m. and 4 p.m., Monday through Friday.

FOR FURTHER INFORMATION CONTACT: Sharon A. Carayannis, Center for Biologics Evaluation and Research (HFM–635), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–594–3074.

SUPPLEMENTARY INFORMATION:

On January 21 through 22, 1992, FDA sponsored a public workshop on QA in the manufacture of blood and blood products and provided a background information document on quality assurance to all registrants. That workshop was announced in the Federal Register on December 13, 1991 (56 FR 65094). FDA developed the “Draft Guideline for Quality Assurance in Blood Establishments,” dated June 17, 1993, following the meeting, after considering the discussions at the workshop and comments received. FDA announced the availability of the draft guideline in the Federal Register on July 2, 1993 (58 FR 35959), and solicited comments. FDA has revised the draft guideline in response to public comment. The revisions are minor and intended to clarify the document. This guideline, dated July 14, 1995, provides general information on procedures and practices and may be useful to blood establishments in developing and administering a QA program.

To ensure the continued safety of the nation’s blood supply, it is essential that blood establishments implement effective control over manufacturing processes and systems. FDA believes that this can be accomplished by each blood establishment developing a well planned, written, and managed QA program designed to recognize and prevent the causes of recurrent deficiencies in blood establishment performance. The emphasis of such a QA program is on preventing errors rather than detecting them retrospectively. The potential public health consequences require that all establishments, regardless of size, invest in QA.

The guideline includes discussions of the following: (1) The general concepts of a quality control/assurance program; (2) the function and reporting responsibilities of the QA unit; (3) the responsibilities of the QA unit in such areas as standard operating procedures, training and education, competency evaluation, proficiency testing, validation, equipment, error/accident reports, records management, lot release procedures and QA audits; and (4) the
biological product and CGMP regulations for blood and blood components in 21 CFR parts 600 through 680, and the CGMP regulations in 21 CFR parts 210 through 211. In addition, the guideline contains a glossary, a reference page, and an appendix that provides examples of the regulations in 21 CFR parts 210, 211, and 21 CFR parts 600 through 680 supplementing each other.

This document is not being issued under the authority of 21 CFR 10.90(b) because FDA is in the process of revising this section. This document, although called a guideline, does not bind the agency and does not create or confer any rights, privileges, or benefits for or on any person. Blood establishments may follow the guideline or may choose to use alternative procedures not provided in the guideline. If a blood establishment chooses to use alternative procedures, the establishment may wish to discuss the matter further with the agency to prevent expenditure of resources on activities that may be unacceptable to FDA.

Interested persons may, at any time, submit written comments to the Dockets Management Branch (address above) regarding this guideline. Two copies of any comments are to be submitted except that individuals may submit one copy. Comments are to be identified with the docket number found in brackets in the heading of this document. Continued comment by the blood industry is encouraged, and comments will be continuously accepted by the Dockets Management Branch.

FDA periodically will review written comments on this guideline to determine whether future revisions to the guideline are warranted.


William B. Schultz,
Deputy Commissioner for Policy.

[FR Doc. 95-17346 Filed 7-13-95; 8:45 am]

BILLING CODE 4160-01-F

[Docket No. 93E-0076]

Determination of Regulatory Review Period for Purposes of Patent Extension; RENORMAX®

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) has determined the regulatory review period for RENORMAX® and is publishing this notice of that determination as required by law. FDA has made the determination because of the submission of an application to the Commissioner of Patents and Trademarks, Department of Commerce, for the extension of a patent which claims that human drug product.

ADDRESSES: Written comments and petitions should be directed to the Dockets Management Branch (HFA-305), Food and Drug Administration, rm. 1–23, 12420 Parklawn Dr., Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Brian J. Malkin, Office of Health Affairs (HFY–20), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–443–1382.

SUPPLEMENTARY INFORMATION: The Drug Price Competition and Patent Term Restoration Act of 1984 (Pub. L. 98–417) and the Generic Animal Drug and Patent Term Restoration Act (Pub. L. 100–670) generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.

A regulatory review period consists of two periods of time: a testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the actual amount of extension that the Commissioner of Patents and Trademarks may award (for example, half the testing phase must be subtracted as well as any time that may have occurred before the patent was issued), FDA's determination of the length of a regulatory review period for a human drug product will include all of the testing phase and approval phase as specified in 35 U.S.C. 156(g)(1)(B).

FDA recently approved for marketing the human drug product RENORMAX® (spiraipril hydrochloride). RENORMAX® is indicated for the treatment of hypertension. Subsequent to this approval, the Patent and Trademark Office received a patent term restoration application for RENORMAX® (U.S. Patent No. 4,470,972) from Schering Corp., and the Patent and Trademark Office requested FDA's assistance in determining this patent's eligibility for patent term restoration. In a letter dated April 12, 1995, FDA advised the Patent and Trademark Office that this human drug product had undergone a regulatory review period and that the approval of RENORMAX® represented the first permitted commercial marketing or use of the product. Shortly thereafter, the Patent and Trademark Office requested that FDA determine the product's regulatory review period.

FDA has determined that the applicable regulatory review period for RENORMAX® is 3,996 days. Of this time, 2,901 days occurred during the testing phase of the regulatory review period, while 1,095 days occurred during the approval phase. These periods of time were derived from the following dates:

1. The date an exemption under section 505(i) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(i)) became effective: January 22, 1984. FDA has verified the applicant's claim that the date the investigational new drug application (IND) became effective was on January 22, 1984.

2. The date the application was initially submitted with respect to the human drug product under section 505(b) of the Federal Food, Drug, and Cosmetic Act: December 31, 1991. FDA has verified the applicant's claim that the new drug application (NDA) for RENORMAX® (NDA 20–240) was initially submitted on December 31, 1991.

3. The date the application was approved: December 29, 1994. FDA has verified the applicant's claim that NDA 20–240 was approved on December 29, 1994.

This determination of the regulatory review period establishes the maximum potential length of a patent extension. However, the U.S. Patent and Trademark Office applies several statutory limitations in its calculations of the actual period for patent extension. In its application for patent extension, this applicant seeks 730 days of patent term restoration.

Anyone with knowledge that any of the dates as published is incorrect may, on or before September 12, 1995, submit to the Dockets Management Branch (address above) written comments and ask for a redetermination. Furthermore, any interested person may petition FDA, on or before January 15, 1996, for a determination regarding whether the applicant for extension acted with due diligence during the regulatory review period. To meet its burden, the petition...